Fig 2From: Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control studyFlowchart for inclusion and exclusion of patients. TKI, tyrosine kinase inhibitors; PD, progressive diseaseBack to article page